CA2935630A1 - Frizzled receptor antibodies for treatment of cancer - Google Patents

Frizzled receptor antibodies for treatment of cancer Download PDF

Info

Publication number
CA2935630A1
CA2935630A1 CA2935630A CA2935630A CA2935630A1 CA 2935630 A1 CA2935630 A1 CA 2935630A1 CA 2935630 A CA2935630 A CA 2935630A CA 2935630 A CA2935630 A CA 2935630A CA 2935630 A1 CA2935630 A1 CA 2935630A1
Authority
CA
Canada
Prior art keywords
antibody
tumor
seq
antigen
isolated antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2935630A
Other languages
English (en)
French (fr)
Inventor
Benjamin Dekel
Naomi Podde-Shakked
Orit Harari-Steinberg
Michal MARK-DANIELI
Einav VAX
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Tel HaShomer Medical Research Infrastructure and Services Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Tel HaShomer Medical Research Infrastructure and Services Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Tel HaShomer Medical Research Infrastructure and Services Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CA2935630A1 publication Critical patent/CA2935630A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2935630A 2014-01-02 2015-01-01 Frizzled receptor antibodies for treatment of cancer Abandoned CA2935630A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461922893P 2014-01-02 2014-01-02
US61/922,893 2014-01-02
PCT/IL2015/050009 WO2015101998A1 (en) 2014-01-02 2015-01-01 Frizzled receptor antibodies for treatment of cancer

Publications (1)

Publication Number Publication Date
CA2935630A1 true CA2935630A1 (en) 2015-07-09

Family

ID=53493369

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2935630A Abandoned CA2935630A1 (en) 2014-01-02 2015-01-01 Frizzled receptor antibodies for treatment of cancer

Country Status (6)

Country Link
US (1) US10465004B2 (cg-RX-API-DMAC7.html)
EP (1) EP3089995A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017506214A (cg-RX-API-DMAC7.html)
CA (1) CA2935630A1 (cg-RX-API-DMAC7.html)
IL (1) IL246540A0 (cg-RX-API-DMAC7.html)
WO (1) WO2015101998A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3089995A4 (en) 2014-01-02 2017-11-29 Tel HaShomer Medical Research Infrastructure and Services Ltd. Frizzled receptor antibodies for treatment of cancer
WO2017100154A1 (en) * 2015-12-07 2017-06-15 Purdue Research Foundation Inhibitors for proliferating cell nuclear antigen and uses
CN112159474B (zh) * 2019-11-06 2021-11-19 上海健康医学院 一种靶向Frizzled7人源化抗体及其制备方法与应用
WO2026051924A1 (zh) * 2024-09-03 2026-03-12 浙江道尔生物科技有限公司 抗fzd7单域抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867705B2 (en) * 2004-09-21 2011-01-11 Rhode Island Hospital, A Lifespan-Partner Frizzled proteins and detection and treatment of cancer
EP2500360B1 (en) * 2005-10-31 2015-08-05 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP2331136B1 (en) * 2008-09-26 2018-01-10 OncoMed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
WO2011004379A1 (en) * 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
EP3089995A4 (en) 2014-01-02 2017-11-29 Tel HaShomer Medical Research Infrastructure and Services Ltd. Frizzled receptor antibodies for treatment of cancer

Also Published As

Publication number Publication date
WO2015101998A1 (en) 2015-07-09
EP3089995A1 (en) 2016-11-09
US20160326245A1 (en) 2016-11-10
IL246540A0 (en) 2016-08-31
EP3089995A4 (en) 2017-11-29
JP2017506214A (ja) 2017-03-02
US10465004B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
US9109024B2 (en) Anti-RSPO1 antibodies and uses thereof
US9598497B2 (en) RSPO3 binding agents and uses thereof
AU2011205409B2 (en) Wnt-binding agents and uses thereof
DK2481756T3 (en) Compositions and Methods for Diagnosing and Treating Cancer
MX2012011323A (es) Agentes que se unen al receptor encrespado y usos de los mismos.
US20170266276A1 (en) Combination Therapy For Treatment of Cancer
US20170247465A1 (en) Combination therapy for treatment of cancer
US10465004B2 (en) Frizzled receptor antibodies for treatment of cancer
US20170247437A1 (en) Rspo1 binding agents and uses thereof
HK1178915A (en) Wnt-binding agents and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20210831